

Accepted Manuscript

Prevention of adverse pulmonary, neurological and ocular perinatal outcomes by supplementing omega-3 fatty acids during pregnancy

Lorenzo Ferro Desideri, MD, Fabio Barra, MD, Simone Ferrero, MD PhD



PII: S0002-9378(18)30233-3

DOI: [10.1016/j.ajog.2018.03.019](https://doi.org/10.1016/j.ajog.2018.03.019)

Reference: YMOB 12109

To appear in: *American Journal of Obstetrics and Gynecology*

Received Date: 14 February 2018

Accepted Date: 21 March 2018

Please cite this article as: Ferro Desideri L, Barra F, Ferrero S, Prevention of adverse pulmonary, neurological and ocular perinatal outcomes by supplementing omega-3 fatty acids during pregnancy, *American Journal of Obstetrics and Gynecology* (2018), doi: 10.1016/j.ajog.2018.03.019.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Title: Prevention of adverse pulmonary, neurological and ocular perinatal outcomes by supplementing omega-3 fatty acids during pregnancy

Authors: Lorenzo FERRO DESIDERI MD ^{1,2}, Fabio BARRA MD ^{1,2}, Simone FERRERO MD PhD ^{1,2}

Institutions:

¹ Academic Unit of Obstetrics and Gynecology, Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132 Genoa, Italy

² Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Italy

Corresponding Author:

Simone Ferrero MD, PhD; Academic Unit of Obstetrics and Gynecology, IRCCS AOU San Martino – IST, Largo R. Benzi 10, 16132 Genoa, Italy

Telephone 01139 010 511525

Mobile 01139 3477211682

Fax 01139 010511525

E-mail: simone.ferrero@unige.it

Conflicts of interest: Lorenzo Ferro Desideri, Fabio Barra, Simone Ferrero reported no conflicts of interest.

Funding: The paper was not funded.

Word count: 396

To the Editor:

We read with great interest the recent study published by Kuper *et al.*¹, where the authors randomized pregnant smokers and non-smokers women to receive intramuscularly either 17 alpha-hydroxyprogesterone caproate, an omega-3 fatty acid, or placebo from the 16-20th week of gestation till the delivery, evaluating its effect on the preterm delivery rate and both maternal and neonatal complications.

The authors should be congratulated for the randomized study design and the presence of ethnic variability in the examined population, and, nonetheless, to have found a significant reduction of the spontaneous preterm delivery rate and low birth weight thanks to the anti-oxidative agent supplementation in smoker mothers in comparison to non-smokers¹.

However, we would like to point out some methodological concerns on the prevention of the secondary outcomes examined in the study, in particular dealing with neonatal complications. The authors did not report a significant treatment effect in reducing neonatal complications both in the groups of smokers and not smokers¹. Concerning this finding, we believe that the smokers population receiving antioxidant supplementation is relatively small (64/851) and, therefore, the statistical power of the study could have been limited by the small sample size. In contrast with the findings in this study, in the literature it is well known the positive association between the oxidative damage due to maternal smoke and the increased incidence of neonatal complications such as bronchopulmonary dysplasia (BPD), intraventricular hemorrhage, and retinopathy of prematurity². On this regard, several clinical studies showed that the maternal supplementation of vitamin A, which exerts antioxidant activity, during the late phase of pregnancy, is effective in decreasing BPD incidence in newborns³. Moreover, in line with this findings, Sharma *et al.* found in the rat model that the maternal supplementation with polyunsaturated fatty acids ω -3 (PUFA ω -3) decreases significantly the neonatal onset of BPD, especially protecting the reduction of alveolarization caused by the hyperoxia-induced oxidative damage⁴.

Given these assumptions, we deem that omega-3 fatty acid supplementation should be more thoroughly investigated for preventing the onset of neonatal complications for at least two reasons: firstly, their efficacy in reducing significantly the preterm delivery rate in smoker mothers and secondly through the already proven protective effect during pregnancy. Thus, further larger scale studies should be performed in order to better understand the potential effect of antioxidant agents administration in pregnancy of smoker women.

BIBLIOGRAPHY

1. Kuper SG, Abramovici AR, Jauk VC, Harper LM, Biggio JR, Tita AT. The effect of omega-3 supplementation on pregnancy outcomes by smoking status. *Am J Obstet Gynecol*. 2017;217:476.e1-.e6.
2. Wagijo MA, Sheikh A, Duijts L, Been JV. Reducing tobacco smoking and smoke exposure to prevent preterm birth and its complications. *Paediatr Respir Rev*. 2017;22:3-10.
3. Babu TA, Sharmila V. Vitamin A supplementation in late pregnancy can decrease the incidence of bronchopulmonary dysplasia in newborns. *J Matern Fetal Neonatal Med*. 2010;23:1468-9.
4. Sharma D, Nkembi AS, Aubry E, et al. Maternal PUFA omega-3 Supplementation Prevents Neonatal Lung Injuries Induced by Hyperoxia in Newborn Rats. *Int J Mol Sci*. 2015;16:22081-93.